We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
-19.47%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$37.5M
AUM Growth
-$78.6M
Cap. Flow
+$14M
Cap. Flow %
37.37%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$14M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$20.9K

Sector Composition

Rank Sector Weight
1 Healthcare 93.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.6M 38.85%
+662,063
New +$14M
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.71B
$12.6M 33.57%
982,270
-1,300
-0.1% -$20.9K
ARGS
3
DELISTED
Argos Therapeutics, Inc.
ARGS
$5.98M 15.97%
662,114
– –
ARGS
4
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$2.31M 6.17%
256,030
– –
TARA icon
5
Protara Therapeutics
TARA
$229M
$2.04M 5.44%
29,134
– –

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q1 2017 Portfolio in Review

As of Q1 2017, Pharmstandard International held 5 positions worth $37.5M, down 68% from $116M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pharmstandard International deployed $14M of net new capital in Q1 2017, opening 1 new position. Its largest new stake was Jounce Therapeutics, Inc. Common Stock: 662,063 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 76% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $20.9K trimmed.

  • Pharmstandard International's largest Q1 2017 buy was Jounce Therapeutics, Inc. Common Stock: 662,063 shares worth $14.6M.
  • Pharmstandard International's biggest Q1 2017 reduction was Protagonist Therapeutics, cutting an estimated $20.9K.
  • Pharmstandard International's ten largest holdings make up 100% of its $37.5M portfolio in Q1 2017.
  • Pharmstandard International opened 1 new position and closed 0 in Q1 2017.
  • Pharmstandard International's portfolio value fell 68% quarter-over-quarter to $37.5M.

Based on Pharmstandard International's 13F filing for Q1 2017, filed 12 May 2017.